NL-OMON55053招募中不适用
*Deep phenotyping of the gut immune system during Immune Checkpoint Inhibitor therapy* (DEFENCE) - The gut immune system during immunotherapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •18 years or older
- •Written informed consent
- •Evaluable according to iRECIST v1.1
- •Indication for treatment with anti-PD-1 ICI or a combination of anti-PD-1 and
- •anti-CTLA-4 ICI
- •for locally advanced or metastatic cancer for which no curative local
- •treatment is available.
- •Informed consent to participate in Oncolifes Immunotherapy or POINTING
排除标准
- •Concomitant, chronic or infectious illness in the past 6 months causing
- •moderate to severe colitis
- •Use of a medication in the past 6 months with a known elevated risk of
- •developing moderate to severe colitis (such as mycophenolate mofetil)
- •Gastrointestinal resection
- •Ileostomy or colostomy
- •Abdominal radiotherapy in the past 6 months
研究者
相似试验
进行中（未招募）
不适用
The Gut Immune System During Immune Checkpoint Inhibitor TherapyCancerNCT04600180University Medical Center Groningen38
招募中
不适用
Analysis of intestinal immune cells in patients with inflammatory bowel diseaseJPRN-UMIN000043782Okayama University Hospital100
招募中
不适用
Analyses of immune status of patients with gastrointestinal cancerJPRN-UMIN000019129ational Cancer Center Hospital East300
已完成
不适用
The influence of the gut microbiome on immunity mediated by COVID-19 vaccinatiohealthy volunteersDRKS00027050Institut für Prävention und Tumorepidemiologie143
尚未招募
2 期
Examinations for immune-biological mechanism of anti-atherosclerotic effects of omega 3 lipid formula, Lotriga, focusing on commensal microbe and serum auto-antibodies.The subjects with hyper-triglyceridemia and atherosclerosis.JPRN-UMIN000032320Yokohama City University Graduate School of Medicine, Department of Medical Science and Cardio-Renal Medicine36